RadarScreener › PTHS

PTHS

Pelthos Therapeutics Inc.
NYSE · Biological Products, (No Diagnostic Substances) · EDGAR filings (CIK 1919246) · 8 signals · 0 setups · updated Aug 16, 2026

What the filings say Pressure ▼

The company says its prior financial statements should not be relied on; a restatement follows.

Radar 67 (elevated attention) · dilution pressure elevated · listing risk elevated · governance risk high · runway 6.9 mo · strongest signal: Restatement (non-reliance) (Aug 13, 2026)

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

67Radar · attention score (0–100)
46Dilution pressure · financing + balance sheet
41Listing risk · exchange standards
84Governance risk · reporting, auditor, going concern

Analyst note

No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.

Pro on PTHS
Alerts
One email the morning PTHS files anything that matches your rules (types, minimum score, setups).
12-month history
Every signal and setup for PTHS back a year, not just 30 days — see how the current setup built.
Full analyst notes
What we noticed, evidence with links, what could prove us wrong, red-team caveats.
Full screener + CSV
All 985 flagged companies, same-day, sortable and exportable.
Get Pro · $18.85/mo founding rate   See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$24.2Mcash + short-term investments as of Jun 30, 2026
6.9 moestimated runway (annualized 180-day YTD operating cash flow [companyfacts])
$-1.5Mstockholders' equity as of Jun 30, 2026
$6.7Mpublic float (10-K cover)
3.8Mshares outstanding as of Aug 10, 2026 · was 3.5M May 11, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

DateSignalEvidenceScore
Aug 13, 2026 Restatement (non-reliance) 8-K Item 4.02 filed 2026-08-13 (accepted 07:00 ET) filing 69
Aug 13, 2026 Restatement (non-reliance) “nonreliance” language in 8-K (8-K) filed 2026-08-13 filing 38
Aug 13, 2026 Going-concern language “going concern periodic” language in 10-Q (10-Q) filed 2026-08-13 filing 21
Aug 13, 2026 Going-concern language “going concern periodic” language in 10-Q/A (10-Q/A) filed 2026-08-13 filing 21
Aug 7, 2026 Reverse split “reverse split” language in PRE 14A (PRE 14A) filed 2026-08-07 filing 27
Jun 30, 2026 Negative equity Stockholders' equity $-1,501,000 as of 2026-06-30 filing 31
Jun 30, 2026 Runway 6–12 months ~6.9 months runway: liquidity $24,192,000 as of 2026-06-30, burn $42,157,500/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing 26
Jun 30, 2026 Near $5M MVLS floor Public float $6,700,000 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing 24
Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans